<DOC>
	<DOCNO>NCT00043381</DOCNO>
	<brief_summary>To compare safety efficacy profile decitabine supportive care adult advanced-stage myelodysplastic syndrome ( MDS )</brief_summary>
	<brief_title>Decitabine Versus Supportive Care Adults With Advanced-stage MDS</brief_title>
	<detailed_description>This experimental ( investigational ) study intend answer question whether decitabine well supportive care alone delay progression ( worsen ) disease , prolong survival improve overall quality life MDS patient candidate bone marrow transplant ( BMT ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion : MDS ( de novo secondary ) fit recognize FrenchAmericanBritish , FAB , classification chronic myelomonocytic leukemia ( CMML ) WBC &lt; 12,000/mm3 , AND International Prognostic Scoring System ( IPSS ) &gt; /= 0.5 determine CBC , bone marrow assessment bone marrow cytogenetics within 30 day randomization 18 year old Female patient childbearing potential must negative serum hCG within 24 hour prior randomization , must practice medically approve method birth control past 30 day , agree continue practice trial duration must breastfeed ECOG WHO performance status 02 Written informed consent Normal renal hepatic function ( creatinine &lt; /= 2 mg/dL , bilirubin &lt; /= 1.5 mg/dL , SGPT &lt; /= 2 time upper limit normal range ) Exclusion : Acute Myeloid Leukemia ( AML ) ( &gt; /=30 % bone marrow blast ) progressive malignant disease Patients must recover toxic effect prior therapy must chemotherapy minimum 4 week prior study entry protocol ( minimum six week prior nitrosoureas bone marrow transplantation ) Ongoing treatment androgenic hormone , danazol , colonystimulating factor , agent use treat MDS within 7 day study initiation . Administration investigational agent within 30 day precede study initiation . Uncontrolled cardiac disease congestive heart failure Uncontrolled restrictive obstructive pulmonary disease Active viral bacterial infection Superimposed autoimmune hemolytic anemia thrombocytopenia Known positive serology HIV Mental illness condition prevent full cooperation treatment monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>decitabine</keyword>
	<keyword>5-aza-2'deoxycytidine</keyword>
</DOC>